Trial: Neopele

NeoPeLe: neoadjuvant pembrolizumab and lenvatinib in resectable stage III melanoma

Circulating immune cell subsets in patients with melanoma from the OpACIN-neo trial

Breaking News: NETTER-2 Trial Supports Lutathera® as 1st Line Treatment - Dr. Singh Explains

Trial (feat. Popcaan)

Investigators Present Updated Results of the OpACIN Trial for Melanoma

Targeted Oncology

Treating patients with melanoma who progressed on anti-PD-L1 with lenvatinib and pembrolizumab

Georgina Long, ESMO 2022: Highlights in melanoma – SWOG S1801 trial

Touch Medical Media

Clinical trials investigating the treatment of melanoma

NADINA trial: neoadjuvant ipilimumab + nivolumab vs. adjuvant nivolumab in stage III melanoma

Phase 3 Clinical Trial of NAC Launched for RP Patients

Foundation Fighting Blindness

Dr. Schadendorf on Nivolumab/ Ipilimumab Combination Trial in Melanoma

Clinical & tumor characteristics of patients with recurrent melanoma upon immunotherapy

Expert report on neoadjuvant immune checkpoint inhibitors for Melanoma

European Society for Medical Oncology (ESMO)

The IRIS Trial

NOVA Phase III trial of niraparib in platinum-sensitive ovarian cancer patients

Trial design of ENGOT-OV16/NOVA Phase III trial of niraparib in platinum-sensitive ovarian cancer

KEYNOTE-716: pembrolizumab for patients with high-risk stage II melanoma

Rates of pathologic complete response after neoadjuvant datopotamab deruxtecan in neoadjuvant br...

Reducing recurrence of advanced melanoma with pembrolizumab

CheckMate 067: Phase 3 trial of nivolumab in melanoma

EMJ